JP2019519227A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519227A5 JP2019519227A5 JP2018561962A JP2018561962A JP2019519227A5 JP 2019519227 A5 JP2019519227 A5 JP 2019519227A5 JP 2018561962 A JP2018561962 A JP 2018561962A JP 2018561962 A JP2018561962 A JP 2018561962A JP 2019519227 A5 JP2019519227 A5 JP 2019519227A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- protein complex
- soluble fusion
- soluble
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037865 fusion proteins Human genes 0.000 claims 29
- 108020001507 fusion proteins Proteins 0.000 claims 29
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical group 0.000 claims 9
- 102000003812 Interleukin-15 Human genes 0.000 claims 5
- 108090000172 Interleukin-15 Proteins 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 230000027455 binding Effects 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 230000009870 specific binding Effects 0.000 claims 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000014621 translational initiation Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000004556 Interleukin-15 Receptors Human genes 0.000 claims 1
- 108010017535 Interleukin-15 Receptors Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102220311640 rs1382779104 Human genes 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662342311P | 2016-05-27 | 2016-05-27 | |
| US62/342,311 | 2016-05-27 | ||
| US201662397236P | 2016-09-20 | 2016-09-20 | |
| US62/397,236 | 2016-09-20 | ||
| PCT/US2017/034656 WO2017205726A1 (en) | 2016-05-27 | 2017-05-26 | Construction and characterization of multimeric il-15-based molecules with cd3 binding domains |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519227A JP2019519227A (ja) | 2019-07-11 |
| JP2019519227A5 true JP2019519227A5 (enExample) | 2020-06-18 |
| JP7037506B2 JP7037506B2 (ja) | 2022-03-16 |
Family
ID=60412970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561962A Active JP7037506B2 (ja) | 2016-05-27 | 2017-05-26 | Ｃｄ３結合ドメインを有する多量体ｉｌ－１５系分子の構築及び特性評価 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10865230B2 (enExample) |
| EP (1) | EP3464352B1 (enExample) |
| JP (1) | JP7037506B2 (enExample) |
| KR (2) | KR102463844B1 (enExample) |
| CN (2) | CN109496217B (enExample) |
| AU (1) | AU2017271593B2 (enExample) |
| CA (1) | CA3025343A1 (enExample) |
| WO (1) | WO2017205726A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2690825C (en) | 2007-05-11 | 2019-02-12 | Altor Bioscience Corporation | Fusion molecules and il-15 variants |
| CN105017429B (zh) | 2010-09-21 | 2021-04-06 | 阿尔托生物科学有限公司 | 多聚体il-15可溶性融合分子与其制造与使用方法 |
| US11053299B2 (en) | 2010-09-21 | 2021-07-06 | Immunity Bio, Inc. | Superkine |
| CN105263521B (zh) * | 2014-01-15 | 2021-06-29 | 卡德门企业有限公司 | 免疫调节剂 |
| EP3160498B1 (en) | 2014-06-30 | 2021-10-06 | Altor BioScience Corporation | Il-15-based molecules and methods of use thereof |
| CN109496217B (zh) | 2016-05-27 | 2023-10-20 | 阿尔托生物科学有限公司 | 具有cd3结合域的基于多聚体il-15的分子的构造和表征 |
| CA3029813A1 (en) | 2016-06-13 | 2017-12-21 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
| WO2018075989A1 (en) | 2016-10-21 | 2018-04-26 | Altor Bioscience Corporation | Multimeric il-15-based molecules |
| KR20210032924A (ko) | 2017-09-05 | 2021-03-25 | 토크 테라퓨틱스, 인코포레이티드 | 치료용 단백질 조성물 및 그의 제조 및 사용 방법 |
| EP3723787A4 (en) | 2017-12-14 | 2021-09-01 | Bluebird Bio, Inc. | DARIC INTERLEUKIN RECEPTORS |
| TW201938196A (zh) * | 2018-01-18 | 2019-10-01 | 美商南特生物科學股份有限公司 | 融合蛋白擴展 |
| BR112020015202A2 (pt) * | 2018-03-01 | 2020-12-29 | Glycotope Gmbh | Construções de proteínas de fusão compreendendo um anticorpo anti-muc1 e il-15 |
| TW202003011A (zh) | 2018-03-26 | 2020-01-16 | 美商艾爾特生物科技責任有限公司 | 抗ＰＤＬ１、ＩＬ－１５及ＴＧＦ－β受體組合分子 |
| US11267866B2 (en) | 2018-04-04 | 2022-03-08 | Nant Holdings Ip, Llc | Immunoglobulin complex comprising interleukin-15 |
| US12350316B2 (en) | 2018-08-16 | 2025-07-08 | Nantbio, Inc. | IL7-IL 15 TxM compositions and methods |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| WO2021041886A1 (en) * | 2019-08-29 | 2021-03-04 | Nantbio, Inc. | Modified n-810 and methods therefor |
| NZ788210A (en) * | 2019-10-16 | 2025-11-28 | Lg Chemical Ltd | Neonatal fc receptor binding affimers |
| CN111690069B (zh) * | 2019-11-13 | 2022-04-19 | 中国科学技术大学 | 一种IL-15/SuIL-15Rα-mFc-γ4复合体蛋白及其构造方法、应用 |
| CN113135996A (zh) * | 2019-12-09 | 2021-07-20 | 启愈生物技术(上海)有限公司 | 一种双特异抗体及其应用 |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| WO2022042576A1 (zh) * | 2020-08-27 | 2022-03-03 | 盛禾(中国)生物制药有限公司 | 一种多功能融合蛋白及其用途 |
| CN114106195B (zh) * | 2020-08-27 | 2024-09-17 | 盛禾(中国)生物制药有限公司 | 一种多功能融合蛋白及其用途 |
| US20230405122A1 (en) * | 2020-11-24 | 2023-12-21 | City Of Hope | Compositions and uses of psca targeted chimeric antigen receptor modified cells |
| CN112795543B (zh) * | 2021-02-04 | 2022-09-27 | 华中农业大学 | 杂交瘤细胞株及其分泌的抗草鱼IL-15Rα单克隆抗体和应用 |
| KR20230160389A (ko) * | 2021-04-22 | 2023-11-23 | 광동 파폰 바이오파마 인크. | 이중 특이성 다기능 융합 폴리펩티드 |
| EP4349870A1 (en) * | 2021-06-02 | 2024-04-10 | Qure Biotechnology (Shanghai) Co., Ltd. | Anti-cd3 antibody variant, fusion protein, and application |
| CN116574190A (zh) * | 2021-07-30 | 2023-08-11 | 启愈生物技术(上海)有限公司 | 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用 |
| US20240383985A1 (en) * | 2021-09-09 | 2024-11-21 | Qure Biotechnology (Shanghai) Co., Ltd. | Antigen targeting, anti-cd16a, and immune effector cell activating trifunctional fusion protein, and application thereof |
| WO2024197709A1 (zh) * | 2023-03-30 | 2024-10-03 | 中国科学院深圳先进技术研究院 | 一种t细胞衔接器及其制备方法和应用 |
| WO2024233299A2 (en) * | 2023-05-05 | 2024-11-14 | Board Of Regents, The University Of Texas System | Multi-receptor natural killer cells |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| WO1994004689A1 (en) | 1992-08-14 | 1994-03-03 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Recombinant toxin with increased half-life |
| US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US6096871A (en) * | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5534592A (en) | 1995-09-22 | 1996-07-09 | The Goodyear Tire & Rubber Company | High performance blend for tire treads |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US8772451B2 (en) | 2003-11-10 | 2014-07-08 | Altor Bioscience Corporation | Soluble TCR molecules and methods of use |
| EP1586585A1 (de) * | 2004-04-14 | 2005-10-19 | F. Hoffmann-La Roche Ag | Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung |
| CA2690825C (en) | 2007-05-11 | 2019-02-12 | Altor Bioscience Corporation | Fusion molecules and il-15 variants |
| CN101842117A (zh) * | 2007-08-28 | 2010-09-22 | 比奥根艾迪克Ma公司 | 抗igf-1r抗体及其用途 |
| CN105017429B (zh) | 2010-09-21 | 2021-04-06 | 阿尔托生物科学有限公司 | 多聚体il-15可溶性融合分子与其制造与使用方法 |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| MX2016000272A (es) * | 2013-07-12 | 2016-08-03 | Zymeworks Inc | Construcciones de unión a los antígenos cd19 y cd3 biespecificos. |
| EP3160498B1 (en) | 2014-06-30 | 2021-10-06 | Altor BioScience Corporation | Il-15-based molecules and methods of use thereof |
| JP6655061B2 (ja) * | 2014-07-29 | 2020-02-26 | ノバルティス アーゲー | 状態を治療するためのｉｌ−１５およびｉｌ−１５ｒアルファヘテロ二量体用量増加レジメン |
| AU2016326575A1 (en) | 2015-09-25 | 2018-04-12 | Altor Bioscience Corporation | Interleukin-15 superagonist significantly enhances graft-versus-tumor activity |
| CN109496217B (zh) | 2016-05-27 | 2023-10-20 | 阿尔托生物科学有限公司 | 具有cd3结合域的基于多聚体il-15的分子的构造和表征 |
| US20190048055A1 (en) | 2017-03-31 | 2019-02-14 | Altor Bioscience Corporation | Alt-803 in combination with anti-cd38 antibody for cancer therapies |
-
2017
- 2017-05-26 CN CN201780045989.XA patent/CN109496217B/zh active Active
- 2017-05-26 WO PCT/US2017/034656 patent/WO2017205726A1/en not_active Ceased
- 2017-05-26 CN CN202311304218.1A patent/CN117362450A/zh active Pending
- 2017-05-26 EP EP17803651.3A patent/EP3464352B1/en active Active
- 2017-05-26 KR KR1020187037953A patent/KR102463844B1/ko active Active
- 2017-05-26 AU AU2017271593A patent/AU2017271593B2/en active Active
- 2017-05-26 KR KR1020227036271A patent/KR20220148306A/ko not_active Withdrawn
- 2017-05-26 CA CA3025343A patent/CA3025343A1/en active Pending
- 2017-05-26 JP JP2018561962A patent/JP7037506B2/ja active Active
- 2017-05-26 US US15/606,552 patent/US10865230B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519227A5 (enExample) | ||
| JP2019528077A5 (enExample) | ||
| JP2020114828A5 (enExample) | ||
| JP2017504578A5 (enExample) | ||
| IL275743A (en) | New bispecific format suitable for use in high-through-put screening | |
| JP2019033754A5 (enExample) | ||
| JP2020074776A5 (enExample) | ||
| RU2015129640A (ru) | Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1 | |
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| JP2010527919A5 (enExample) | ||
| EA200870555A1 (ru) | Слитые белки, их применение и способы их получения | |
| JP2019516665A5 (enExample) | ||
| JP5874118B2 (ja) | ＩｇＡ結合性ペプチド及びそれによるＩｇＡの精製 | |
| JP2016000731A5 (enExample) | ||
| JP2018537415A5 (enExample) | ||
| JP2018522564A5 (enExample) | ||
| JP2017506882A5 (enExample) | ||
| JP2018528786A5 (enExample) | ||
| JP2009524422A5 (enExample) | ||
| JP2014528696A5 (enExample) | ||
| JP2014158485A5 (enExample) | ||
| EA201400046A1 (ru) | Удаление клеток-мишеней с помощью циркулирующих вирусспецифических цитотоксических т-клеток с использованием содержащих гкгс класса i комплексов | |
| HRP20130877T1 (hr) | Antitijela koja neutraliziraju humani citomegalovirus i njihova primjena | |
| JP2019535315A5 (enExample) | ||
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение |